ReviewThe Korean journal of internal medicine2017
Voriconazole-refractory invasive aspergillosis.
Review in The Korean journal of internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Invasive cerebral aspergillosis in a pregnant woman: a rare case of intracranial giant granuloma.BMC infectious diseases · 2025Article
- An oxylipin signal confers protection against antifungal echinocandins in pathogenic aspergilli.Nature communications · 2024Article
- Septic Obturation of a Knee Endoprosthesis Caused byPathogens (Basel, Switzerland) · 2023Article
- Potential Implication of Azole Persistence in the Treatment Failure of Two Haematological Patients Infected withJournal of fungi (Basel, Switzerland) · 2023Article
- Antifungals: From Pharmacokinetics to Clinical Practice.Antibiotics (Basel, Switzerland) · 2023Review
- Invasive Aspergillosis after Renal Transplantation.Journal of fungi (Basel, Switzerland) · 2023Review
- Nanotechnology-Based Approaches for Voriconazole Delivery Applied to Invasive Fungal Infections.Pharmaceutics · 2023Review
- Fungal brain infection-no longer a death sentence.Neurosurgical review · 2021Article
- Trends onJournal of fungi (Basel, Switzerland) · 2021Article
- Disseminated cerebral aspergillosis complicated by thrombotic microangiopathy.Medical mycology case reports · 2019Article
- Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea.The Korean journal of internal medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive aspergillosis (IA) is one of the most common life-threatening complications in immunocompromised patients. Voriconazole is currently the drug of choice for IA treatment. However, some patients with IA suffer clinical deterioration despite voriconazole therapy. Management of voriconazole-refractory IA remains challenging; no useful recommendations have yet been made. Voriconazole-refractory IA can be further categorized as disease attributable to misdiagnosis or co-infection with another mold; inadequate blood voriconazole blood; inadequate tissue drug concentrations attributable to angioinvasion; immune reconstitution inflammatory syndrome; or infection with voriconazole-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.